PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24582461-7	2014	RESULTS: Extended duration rivaroxaban resulted in higher treatment costs ($22,645 vs. $22,083) but yielded greater QALYs (16.167 vs. 16.134) as compared to placebo; corresponding to an ICER of $17,030/QALY gained.	Rivaroxaban	27-38	cAMP responsive element modulator	Homo sapiens	186-190	
25319314-6	2014	The ICER of rivaroxaban versus warfarin was SG$29,697 (US$26,727) per QALY.	Rivaroxaban	12-23	cAMP responsive element modulator	Homo sapiens	4-8	
25319314-9	2014	Deterministic sensitivity analyses showed that the ICER of rivaroxaban versus warfarin was sensitive to cost of rivaroxaban and utilities for rivaroxaban and warfarin.	Rivaroxaban	59-70	cAMP responsive element modulator	Homo sapiens	51-55	
25319314-9	2014	Deterministic sensitivity analyses showed that the ICER of rivaroxaban versus warfarin was sensitive to cost of rivaroxaban and utilities for rivaroxaban and warfarin.	Rivaroxaban	112-123	cAMP responsive element modulator	Homo sapiens	51-55	
25319314-9	2014	Deterministic sensitivity analyses showed that the ICER of rivaroxaban versus warfarin was sensitive to cost of rivaroxaban and utilities for rivaroxaban and warfarin.	Rivaroxaban	112-123	cAMP responsive element modulator	Homo sapiens	51-55	
22651881-8	2012	The ICER for rivaroxaban was $27,498 per QALY.	Rivaroxaban	13-24	cAMP responsive element modulator	Homo sapiens	4-8